APLI Appili Therapeutics Inc
- 0.035
- 0.0000.00%
Appili Therapeutics Inc News
Appili Therapeutics Q4 Loss Narrows Amid Increase in Government Assistance
Appili Therapeutics (APLI.TO), a biopharmaceutical company focused on drug development for infectious diseases, late on Tuesday said its fiscal fourth-quarter net loss declined by half, mainly because
Appili Therapeutics Announces Additional Bridge Loan From Bloom Burton & Co.
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPin
Appili Therapeutics Signs Definitive Agreement to Be Acquired by Aditxt, Inc.
Appili Therapeutics Notes Researchers Publish Manuscript on Prevention and Emergency Response to Tularemia Outbreaks
Appili Therapeutics Inc. (APLI.TO) on Tuesday announced a publication in the journal Frontiers in Bacteriology on the prevention of tularemia. Appili's Director of Non-Clinical Research, Dr. Carl Gelh
Appili Therapeutics Brief: Announcing Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Providing Update on Bridge Loan
07:27 AM EST, 12/15/2023 (MT Newswires) -- Appili Therapeutics Brief: Announcing Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Providing Update on Bridg
Appili Therapeutics Brief: As of September 30, 2023, Co Had Cash of $0.4 Million, Compared to $2.5 Million on March 31, 2023.
04:29 PM EST, 11/13/2023 (MT Newswires) -- Appili Therapeutics Brief: As of September 30, 2023, Co had cash of $0.4 million, compared to $2.5 million on March 31, 2023.
Appili Therapeutics Brief: Net Loss and Comprehensive Loss of $1.0 Million or $0.01 Loss per Share for the Three Months Ended September 30, 2023
04:28 PM EST, 11/13/2023 (MT Newswires) -- Appili Therapeutics Brief: Net loss and comprehensive loss of $1.0 million or $0.01 loss per share for the Three months ended September 30, 2023
Appili Therapeutics Brief: Announcing U.S. FDA Approval of LIKMEZ (ATI-1501) Metronidazole Oral Suspension
07:55 AM EDT, 09/25/2023 (MT Newswires) -- Appili Therapeutics Brief: Announcing U.S. FDA Approval of LIKMEZ (ATI-1501) Metronidazole Oral Suspension
Appili Therapeutics Brief: Also Noted Government Funding Committed to Enable Appili to Advance Its Biodefense Vaccine Candidate ATI-1701 Towards an IND
04:53 PM EDT, 08/11/2023 (MT Newswires) -- Appili Therapeutics Brief: Also Noted Government funding committed to enable Appili to advance its biodefense vaccine candidate ATI-1701 towards an IND
Press Release: Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2024
Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the "Company" or "Appili"), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced its financial and operational results for the first quarter of its fiscal year 2024, which ended on June 30, 2023.
Appili Therapeutics Secures Contract for ATI-1701 Funding From U.S. Air Force Academy
Appili Therapeutics Inc. (APLI.TO), focused on drug development for infectious diseases and biodefense, on Monday said it has executed the initial contract with the U.S. Air Force Academy (USAFA) for the previously announced funding of the ATI-1701 program.
Appili Therapeutics Inc. Expected to Post FY2023 Earnings of ($0.08) Per Share (TSE:APL)
Appili Therapeutics Inc. (TSE:APL – Get Rating) – Analysts at Zacks Small Cap increased their FY2023 earnings per share (EPS) estimates for shares of Appili Therapeutics in a research note issued to
Appili Therapeutics Inc. (TSE:APL) to Post FY2023 Earnings of ($0.09) Per Share, Zacks Small Cap Forecasts
Appili Therapeutics Inc. (TSE:APL – Get Rating) – Equities researchers at Zacks Small Cap boosted their FY2023 earnings estimates for shares of Appili Therapeutics in a note issued to investors on
Analysts Issue Forecasts for Appili Therapeutics Inc.'s FY2023 Earnings (TSE:APL)
Appili Therapeutics Inc. (TSE:APL – Get Rating) – Stock analysts at Zacks Small Cap issued their FY2023 earnings per share (EPS) estimates for shares of Appili Therapeutics in a report released on
Appili Therapeutics Inc. (TSE:APL) Forecasted to Post FY2023 Earnings of ($0.10) Per Share
Appili Therapeutics Inc. (TSE:APL – Get Rating) – Zacks Small Cap issued their FY2023 earnings estimates for Appili Therapeutics in a note issued to investors on Thursday, July 14th. Zacks Small C
Appili Therapeutics Inc. Forecasted to Post Q1 2023 Earnings of ($0.03) Per Share (TSE:APL)
Appili Therapeutics Inc. (TSE:APL – Get Rating) – Equities researchers at Zacks Small Cap issued their Q1 2023 earnings per share (EPS) estimates for shares of Appili Therapeutics in a research not
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the "Company" or "Appili"), a biopharmaceutical company developing anti-infective drug candidates, today annou
BRIEF-Appili Therapeutics Reports Financial And Operational Results For Second Quarter Of Fiscal Year 2022 And Change Of Chief Financial Officer
Nov 12 (Reuters) - Appili Therapeutics Inc APLI.TO :* APPILI THERAPEUTICS REPORTS FINANCIAL AND OPERATIONAL RESULTS FOR SECOND QUARTER OF FISCAL YEAR 2022 AND CHANGE OF CHIEF FINANCIAL OFFICER* APPIL
Aditxt Acquisition-Partner's At-Home COVID-19 Drug Fails In Late-Stage Trial
Aditxt Inc (NASDAQ:ADTX) has announced data from Phase 3 PRESECO trial evaluating oral Avigan/Reeqonus (favipiravir) as a potential at-home therapy for mild-to-moderate COVID-19, run by Appili Therape
Appili Therapeutics Says Phase 3 PRESECO Clinical Trial Did Not Meet Primary Endpoint
07:52 AM EST, 11/12/2021 (MT Newswires) -- Appili Therapeutics Inc. (APLI.TO), an infectious disease biopharmaceutical company, on Friday announced that the Phase 3 PRESECO (PREventing SEvere COVID-1
